secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054513
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M
--------------------------------------------------------------------------------

- Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).
- clonoSEQ test volume rose 41% to 17,040; net loss improved to $47.5M from $57.7M.
- Cash $308.9M; FY2024 MRD revenue guidance raised to $135-140M, opex lowered to $350-360M.
- FDA ODAC unanimously supported MRD as primary endpoint for accelerated approval in multiple myeloma.
- Strategic move: MRD and Immune Medicine to report separately; antibody discovery launched for MS and type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/0000950170-24-054513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024054513/adpt-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer